ArticleScientific reports2025
A longitudinal study on the impact of cadmium exposure on quality of life in esophageal squamous cell carcinoma patients in Southern China.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Despite evidence linking cadmium (Cd) to poor cancer outcomes, its association with quality of life in esophageal squamous cell carcinoma (ESCC) patients remains unexplored. This study aimed to investigate the association. This prospective cohort analysis includes 414 newly diagnosed ESCC patients with a 6.5-year follow-up. The EORTC QLQ-C30 and EORTC QLQ-OES18 were used to assess health-related quality of life (HRQoL). The QoLR package was used to calculate the HRQoL scores and determine time to deterioration(TTD) events. The effect of plasma Cd level on the HRQoL was assessed using Cox regression analysis. In the longitudinal TTD analysis, after controlling for potential confounders (age, gender, tumor location, clinical/pathological stage, and treatment modalities), higher plasma Cd levels were consistently associated with a significantly increased risk of deterioration in emotional functioning(HR = 1.466, 95%CI:1.079-1.993), eating problems(HR = 1.440, 95%CI: 1.054-1.968), choking when swallowing(HR = 1.637, 95% CI: 1.194-2.244), and trouble with taste(HR = 1.525, 95%CI: 1.093-2.128). These associations remained robust after adjustment for lifestyle and socioeconomic factors and were validated by bootstrap resampling analysis. Plasma Cd level may be a contributing factor to the deterioration of multiple HRQoL indicators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.